ALDEN, an Algorithm for Assessment of Drug Causality in Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Comparison With Case–Control Analysis

Sassolas, B.; Haddad, C.; Mockenhaupt, Maja; Dunant, Ariane; Liss, Yvonne; Bork, Konrad; Haustein, U.-F.; Vieluf, D.; Roujeau, Jean‐Claude; Louët, Hervé Le

doi:10.1038/clpt.2009.252

Cited by 545 publications

(451 citation statements)

References 27 publications

(42 reference statements)

Supporting

Mentioning

430

Contrasting

Unclassified

Order By: Relevance

“…In 2010, an algorithm of drug causality for epidermal necrolysis (ALDEN) was suggested [29]. The results of ALDEN were found to be consistent with those of the EuroSCAR study.…”

Section: Diagnosismentioning

confidence: 67%

Zespół toksycznej nekrolizy naskórka

Hinc-Kasprzyk¹,

Polak-Krzemińska²,

Ożóg-Zabolska³

2015

Anaesthesiol Intensive Ther

View full text Add to dashboard Cite

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), also known as Lyell's syndrome, are rare, life-threatening diseases that are characterised by extensive epidermal detachment, erosion of mucous membranes and severe systemic symptoms. In the majority of cases, the development of symptoms can be attributed to the use of drugs; therefore, the disease pathology is thought to be caused by a severe adverse reaction to drugs. The high mortality rate results primarily from the development of complications in the form of systemic infections and multiple organ failure. TEN and SJS affect all age groups, including newborns, infants and older children. The rarity of these syndromes has not permitted large, randomised studies, which has resulted in numerous difficulties in their diagnosis and management. Because the pathogenesis has not yet been established, the management and systemic treatment of these syndromes have not been standardised. The efficacy of the treatment options suggested has not been confirmed by clinical studies involving suitably large groups of patients, especially children.

show abstract

“…In 2010, an algorithm of drug causality for epidermal necrolysis (ALDEN) was suggested [29]. The results of ALDEN were found to be consistent with those of the EuroSCAR study.…”

Section: Diagnosismentioning

confidence: 67%

Zespół toksycznej nekrolizy naskórka

Hinc-Kasprzyk¹,

Polak-Krzemińska²,

Ożóg-Zabolska³

2015

Anaesthesiol Intensive Ther

View full text Add to dashboard Cite

show abstract

“…Baseline demographic, co-morbidity, drug causality assessments (algorithm for assessment of drug causality [ALDEN] [9]), clinical characteristics, treatment/outcomes, ADR committee record, electronic medical record (EMR) and outpatient (primary care) allergy records were collated for each patient.…”

Section: Glp-1 Metforminmentioning

confidence: 99%

Poor reporting and documentation in drug‐associated Stevens‐Johnson Syndrome and Toxic Epidermal Necrolysis – Lessons for medication safety

Goldblatt

Khumra

Booth

et al. 2016

Brit J Clinical Pharma

View full text Add to dashboard Cite

“…Severe CARs described for methotrexate and pemetrexed were variously reported under the name TEN syndrome or TEN-like dermatosis (29,30). Conceptually, the pathobiology of the two conditions may be different (33)(34)(35)(36)(37)(38)(39)(40). However, the treatment modalities remain to be determined (38,39).…”

Section: Cutaneous Adverse Reactionsmentioning

confidence: 99%

Revisiting cutaneous adverse reactions to pemetrexed

et al. 2011

View full text Add to dashboard Cite

Abstract. Pemetrexed (Alimta ® ) is a multitargeted antifolate drug approved as a single agent or in combination with cisplatin for the treatment of a small number of malignancies including advanced and metastatic non-squamous non-small cell lung cancer (NSCLC), and malignant pleural mesothelioma. This review reports the recent peer-reviewed publications and original findings regarding cutaneous adverse reactions (CARs) to pemetrexed. Pemetrexed-related CARs are frequently reported under the unspecific term 'skin rash'. However, more specific diseases were tentatively identified as alopecias, urticarial vasculitis, acute generalized exanthematous pustulosis, toxic epidermal necrolysis, radiation recall dermatitis and pityriasis lichenoides. Most of the skin reactions occur shortly after pemetrexed administration. As with methotrexate-related CARs, the cell cycle arrest in the S phase may be regarded as a direct and major cause of the cytotoxic pathobiology. An adverse immune reaction is unlikely. In conclusion, pemetrexed is responsible for CARs exhibiting a variety of clinical presentations. Their origin is likely attributed to direct cytotoxicity following the cell cycle arrest in the S phase and cell necrosis.

show abstract

ALDEN, an Algorithm for Assessment of Drug Causality in Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Comparison With Case–Control Analysis

Cited by 545 publications

References 27 publications

Zespół toksycznej nekrolizy naskórka

Zespół toksycznej nekrolizy naskórka

Poor reporting and documentation in drug‐associated Stevens‐Johnson Syndrome and Toxic Epidermal Necrolysis – Lessons for medication safety

Revisiting cutaneous adverse reactions to pemetrexed

Contact Info

Product

Resources

About